Idience Overview

  • Founded
  • 2019

Founded
  • Status
  • Private

  • Employees
  • 14

Employees
  • Latest Deal Type
  • Early Stage VC

  • (Upcoming)
  • Investors
  • 6

Idience General Information

Description

Developer of oncology drugs intended to deliver breakthroughs that drive innovation and transform cancer treatment. The company's drug is a potent inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells, enabling cancer patients by targeting multiple solid tumors as monotherapy and for combination with other anti-cancer agents.

Contact Information

Website
www.idience.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2, Baumoe-ro 27-gil
  • Seocho-gu
  • Seoul, 06752
  • South Korea
+82 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Idience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC Upcoming Clinical Trials - Phase 2
1. Early Stage VC (Series B) 01-Oct-2020 000.00 000.00 Completed Clinical Trials - Phase 2
To view Idience’s complete valuation and funding history, request access »

Idience Patents

Idience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220117961-A1 Pharmaceutical composition comprising phthalazinone derivatives Pending 16-Oct-2020 0000000000
US-20210323945-A1 Crystalline forms of phthalazinone compound Granted 21-Apr-2020 0000000000
US-11390608-B2 Crystalline forms of phthalazinone compound Active 21-Apr-2020 0000000000
US-20210323946-A1 Process for preparing a phthalazinone derivative and intermediates thereof Pending 21-Apr-2020 0000000000
US-9844550-B2 Phtalazinone derivatives and manufacturing process thereof Active 13-Sep-2013 A61K31/502 00
To view Idience’s complete patent history, request access »

Idience Executive Team (6)

Name Title Board Seat Contact Info
Won Lee Chief Executive Officer
Jinsik Suh Chief Financial Officer
Eun-Jihn Roh Chief Development Officer
Alan Choi Chief Scientific Officer
Kyoung Ha Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Idience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Idience Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DAYLI Partners Venture Capital Minority 000 0000 000000 0
Kiwoom Securities Company Corporation Minority 000 0000 000000 0
Mirae Asset Capital Asset Manager Minority 000 0000 000000 0
Seoul Investment Partners Venture Capital Minority 000 0000 000000 0
T.S. Investment PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »